Our Work in the Field of Immunology

Approximately 150,000 people in Switzerland are affected by the chronic, inflammatory, rheumatic diseases rheumatoid arthritis and ankylosing spondylitis, also known as Bechterew's disease, and over 40,000 people suffer from chronic inflammatory bowel diseases. Many of these diseases are painful, get worse over time and flare up periodically. Even though the introduction of biological drugs has led to major advances in the treatment, no cure is possible.


Over 150'000 people in Switzerland suffer from chronic, inflammatory, rheumatic diseases.

Rheumatic or ‘musculoskeletal’ diseases often affect joints, but in principle can concern every organ of the body. Many of the approximately 200 different diseases are painful and prolonged, get worse over time, and can even result in disability.

Learn more


Over 40'000 people in Switzerland suffer from chronic inflammatory bowel diseases.

Chronic inflammatory bowel diseases are episodically recurring or continuously occurring inflammatory changes to the intestines. Symptoms such as blood in the stool, diarrhea, and tiredness make it hard for patients to live a normal life.

Learn more

«For years, we have been highly committed to researching new treatment options and improving existing ones. In cooperation with our longstanding partners, we develop innovative solutions designed to help affected patients lead the most normal life possible.»

Dr. Ulrike Thull, Director Business Unit Immunology, MSD Switzerland

MSD invests in medical research

For more than 125 years, we have conducted research worldwide so that our medicines and vaccines can contribute to improving our society's health, both now and for future generations. In Switzerland, MSD is currently conducting 23 clinical studies in various therapeutic areas (as of 06/2019).

In order to obtain new knowledge of different symptoms and to help constantly improve the quality of patient treatment, we also invest in clinical research projects run by other organizations. We are financing a registry study by the SCQM Foundation (Swiss Clinical Quality Management in Rheumatic Diseases) that evaluates patient satisfaction using an electronic patient tool, the iDialog app for rheumatic diseases. In the area of chronic inflammatory bowel diseases, we are supporting a study conducted by Helsana that collects data on the illness frequency, mortality rate, comorbidities, health care services, and costs in Switzerland.

Click here to learn more about MSD’s clinical research program in Switzerland.

CH-NON-00239, 10/2019